<DOC>
	<DOCNO>NCT00638989</DOCNO>
	<brief_summary>To compare bioavailability pharmacokinetics CAT-354 follow subcutaneous administration compare IV administration .</brief_summary>
	<brief_title>A Study Assess Bioavailability Pharmacokinetics CAT 354</brief_title>
	<detailed_description>To compare bioavailability pharmacokinetics CAT-354 follow subcutaneous administration 150 mg 300 mg compare 150 mg give intravenously .</detailed_description>
	<criteria>Signed date write informed consent obtain prior study related procedure take place . Males , age 1955 year . No significant abnormality clinical examination medical history ( exclude atopic skin sign , symptom history ) . A normal 12lead ECG ( clinically significant abnormality ) . Clinical chemistry , hematology urinalysis result within laboratory reference range deem clinically significant Investigator ( see Section 11.7 protocol explanation test perform ) . A negative screen drug abuse alcohol . Body mass index ( BMI ) 1830 kg/m2 , inclusive . No clinically significant abnormality history clinical examination ( see also Exclusion Criteria ) . Able comply requirement protocol . Any active concomitant disease include psychological disorder . History medication might carry effect study . Previously receive monoclonal antibody , similar relate protein , might sensitize subject CAT354 . Participation another investigational medicinal product study within three month start study five half live previously administer investigational medicinal product ( IMP ) , whichever long except methodological study IMP give . Any acute illness two week Day 0 ( Visit 2 ) . Any blood donation significant loss blood within 56 day study initiation plasma donation within 7 day study initiation . Subject participate Investigator , subInvestigator , study coordinator , employee participate Investigator , first degree relative aforementioned . Any factor , opinion Investigator , would jeopardize evaluation safety associate poor adherence protocol . The subject 's primary care physician recommend subject take part study . Subjects immunodeficiency disorder Subjects positive test , treat hepatitis B , hepatitis C HIV</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>